Condition (MeSH)
Adrenal Hyperplasia, Congenital
ClinicalTrials.gov lists 99 trials for Adrenal Hyperplasia, Congenital or a narrower condition beneath it. Neurocrine UK Limited has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
99 of the 99 trials are tagged with Adrenal Hyperplasia, Congenital itself; the rest are tagged with a narrower condition beneath it.
When did Adrenal Hyperplasia, Congenital trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 13 |
| 2025 | 5 |
| 2024 | 6 |
| 2023 | 4 |
| 2022 | 6 |
| 2021 | 7 |
| 2020 | 6 |
| 2019 | 4 |
| 2018 | 7 |
| 2017 | 3 |
Showing 10 of 24 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 11 trials starting in 2026 and about 9 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 13 already registered with a 2026 start date: at the cutoff, 4 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.
Prediction, not a registry value: median of 36 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 48 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Adrenal Hyperplasia, Congenital trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 5 |
| Phase 2 | 23 |
| Phase 2/3 | 2 |
| Phase 3 | 9 |
| Phase 4 | 3 |
| Not applicable | 8 |
| Observational | 43 |
How many Adrenal Hyperplasia, Congenital trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 8 |
| Recruiting | 17 |
| Active, not recruiting | 5 |
| Completed | 43 |
| Terminated | 6 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Adrenal Hyperplasia, Congenital trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Neurocrine UK Limited | 8 |
| Neurocrine Biosciences | 6 |
| Spruce Biosciences | 5 |
| Crinetics Pharmaceuticals Inc. | 4 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 4 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Adrenal Hyperplasia, Congenital? (8)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Crinecerfont | 6 |
| Atumelnant | 4 |
| SPR001 | 3 |
| Osilodrostat | 2 |
| Abiraterone | 2 |
Showing 5 of 8 drugs.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Hydrocortisone 1% | 13 |
| Chronocort | 7 |
| Dexamethasone/Dexamethasone acetate | 2 |
| Fludrocortisone/ Fludrocortisone acetate | 2 |
| metabolic balance measurements | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Adrenal Hyperplasia, Congenital trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Gastroenteritis | 8 | 4 |
| Hospitalisation | 8 | 1 |
| Pyrexia | 5 | 4 |
| Adrenocortical insufficiency acute | 4 | 2 |
| Vomiting | 4 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Adrenal Hyperplasia, Congenital? (114)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH. | The Journal of clinical endocrinology and metabolism | 2025 | Yes |
| Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia. | The New England journal of medicine | 2024 | Yes |
| Long-term health consequences of congenital adrenal hyperplasia. | Clinical endocrinology | 2024 | Yes |
| Testicular adrenal rest tumors - Epidemiology, diagnosis and treatment. | Journal of pediatric urology | 2024 | Yes |
| Sexual dimorphism in anxiety is programmed in-utero by sex-steroids: Proof of concept using a disease-model and stress responses to COVID pandemic. | Psychiatry research | 2024 | Yes |
Showing 5 of 114 publications.
Prevalence (57)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Congenital adrenal hyperplasia | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Congenital adrenal hyperplasia | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Congenital adrenal hyperplasia | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Congenital adrenal hyperplasia | Prevalence at birth | 1-9 / 100 000 | United States | US | Unspecified |
| Congenital adrenal hyperplasia | Prevalence at birth | 1-9 / 100 000 | United States | US | Exact |
Showing 5 of 57 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Congenital adrenal hyperplasia | 418 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Congenital adrenal hyperplasia | 418 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.